Oxford Medical Alumni Network
Sign up for mailings - keep in touch with medicine at Oxford.
Update your details - Make sure you receive alumni news and event invitations.
Medical Sciences Division News
University of Oxford and Serum Institute of India agree licence to advance the next-generation multi-stage malaria vaccine candidate component
25 April 2026
The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.
Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease
24 April 2026
Oxford University researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.
Expert comment: World Malaria Day 2026 - Malaria vs the data collective
24 April 2026
Malaria is one of the world’s oldest known diseases, but it is a modern disease too - it continues to kill roughly 600,000 people each year. Most of these people are children, living in Sub-Saharan Africa.
Blood pressure lowering reduces cardiovascular risk across all stages of chronic kidney disease
23 April 2026
A major international study led by researchers at the Nuffield Dept of Women's & Reproductive Health, University of Oxford has found that lowering blood pressure reduces the risk of cardiovascular disease by approximately 9–10% for every 5 mm Hg reduction in systolic blood pressure with consistent benefits across all stages of chronic kidney disease (CKD).
COVID antiviral speeds recovery but doesn't reduce hospitalisation in vaccinated patients, trials find
23 April 2026
The PANORAMIC trial, led from Oxford's Nuffield Department of Primary Care Health Sciences, finds that Paxlovid speeds COVID-19 recovery but does not reduce hospitalisations or deaths in vaccinated higher-risk adults. Published alongside Canada's CanTreatCOVID trial in the New England Journal of Medicine.